`
`FOOD AND DRUG ADMINISTRATION
`
`1
`
`FORTY-SEVENTH MEETING
`
`OF THE
`
`N
`
`0 -
`
`DERMATOLOGIC AND OPHTHALMIC DRUGS ADVISORY C~ITTEE
`
`~
`This transcript has not been edited or corrected,~
`except where relevant for the deletion of materia~
`not releasable under the Freedom of Informatio~
`Act. The Food and Drug Administration makes~
`representation as to its accuracy.
`::::::
`0
`0
`
`8:36 a.m.
`Thursday, September 4, 1997
`
`Versailles I and II
`Holiday Inn
`8120 Wisconsin Avenue
`Bethesda, Maryland
`
`ASSOCIATED REPORTERS OF WASHINGTON
`1523 North Carolina Avenue, N.E.
`Washington, D.C. 20002
`I'" tv ... \
`r A.., A Of\t\
`
`
`
`Page 1 of 271
`
`CFAD VI 1076 - 0001
`CFAD VI v. CELGENE
`IPR2015-01096
`
`
`
`2
`
`APPEARANCES
`
`COMMITTEE MEMBERS:
`
`JOSEPH McGUIRE, JR., M.D., Chairman
`Carol Herzog Professor of Dermatology
`and Pediatrics
`Stanford University School of Medicine
`Department of Dermatology
`MSLS Building, Room P-204
`Stanford, California 94305
`
`TRACY RILEY, Executive Secretary
`Advisors and Consultants Staff
`Center for Drug Evaluation and Research
`Food and Drug Administration
`Chapman Building, Room 200
`5600 Fishers Lane
`Rockville, Maryland 20857
`
`SUSAN COHEN, B.S., Consumer Representative
`3814 Inglemere Drive
`Bethesda, Maryland 20817
`
`MADELEINE DUVIC, M.D.
`Professor of Dermatology
`University of Texas Medical School
`6431 Fannin, MSB 1-186
`Houston, Texas 77030
`
`S. JAMES KILPATRICK, PH.D.
`Professor of Biostatistics
`Medical College of Virginia
`Virginia Commonwealth University
`1101 East Marshall Street
`Sanger Hall, Room B-1-039-A
`Richmond, Virginia 23298-0032
`
`JOEL MINDEL, M.D.
`Director, Neuro-Ophthalmology
`Mt. Sinai Medical Center
`Annenburg Building 22-14, Box 1183
`New York, New York 10029-6574
`
`ASSOCIATED REPORTERS OF WASHINGTON
`1523 North Carolina Avenue, N.E.
`Washington, D.C. 20002
`(202) 543-4809
`
`Page 2 of 271
`
`CFAD VI 1076 - 0002
`
`
`
`-
`
`APPEARANCES
`
`(Continued)
`
`3
`
`COMMITTEE MEMBERS:
`
`(Continued)
`
`MILTON ORKIN, M.D.
`Clinical Professor
`Department of Dermatology
`University of Minnesota
`2733 Huntington Avenue South
`Minneapolis, Minnesota 55416
`
`SPECIAL GOVERNMENT EMPLOYEES, CONSULTANTS
`AND GUEST SPEAKERS:
`
`WILMA BERGFELD, M.D.
`Head, Clinical Research
`Department of Dermatology
`Cleveland Clinic Foundation
`9500 Euclid Avenue
`Cleveland, OH
`44195-5032
`
`COLIN CRAWFORD, M.B., CH.B., MRCP, DTM&H
`Neuromuscular Diseases Department
`Division of Neuroscience and
`Psychological Medicine
`Charing Cross Hospital
`Fulham Palace Road
`London, United Kingdom W6 8RF
`
`KEN HASHIMOTO, M.D.
`Professor and Chair
`Departments of Dermatology and
`Syphilology
`Wayne State University School of Medicine
`4201 St. Antoine
`Detroit, Michigan 48201
`
`W. CHRISTOPHER MATHEWS, M.D., M.S.P.H.
`Antiviral Drugs Advisory Co~mittee Member
`Professor of Clinical Medicine
`University of California at San Diego
`Medical Center
`Mail Code 8681
`200 West Arbor Drive
`San Diego, California 92103-8681
`
`ASSOCIATED REPORTERS OF WASHINGTON
`1523 North Carolina Avenue, N.E.
`Washington, D.C. 20002
`(202) 543-4809
`
`Page 3 of 271
`
`CFAD VI 1076 - 0003
`
`
`
`4
`
`APPEARANCES
`
`(Continued)
`
`SPECIAL GOVERNMENT EMPLOYEES, CONSULTANTS
`AND GUEST SPEAKERS:
`(Continued)
`
`0. FRED MILLER, III, M.D.
`Geisinger Medical Center
`North Academy Avenue
`Danville, Pennsylvania 17822-1406
`
`CYNTHIA MOORE, M.D., PH.D.
`Birth Defects & Genetic Disease Branch
`Centers for Disease Control and
`Prevention, MS-F45
`Atlanta, Georgia 30333
`
`EDWARD J. SHANNON, PH.D.
`G.W. Long Hansen's Disease Center
`P.O. Box 20572
`Baton Rouge, Louisiana 70894
`
`EVA SIMMONS-O'BRIEN, M.D.
`Drugs Assistant Professor of
`Dermatology and Internal Medicine
`Johns Hopkins University School of Medicine
`550 North Broadway, Suite 1002
`Baltimore, Maryland 21287-0900
`
`RANDOLf-rl WARREN
`CEO
`Thalidomide Victims Association of Canada
`P.O. Box 9061 sub 40
`London, Ontario
`Canada N6E
`lVO
`
`-
`
`FOOD AND DRUG ADMINISTRATION STAFF:
`
`DENNIS BASHAW, PHARM.D.
`Biopharmaceutist, Division of Pharmaceutical Evaluation III
`
`DEBRA BIRNKRANT, M.D.
`Acting Director, Division of Antiviral Drug Products
`
`BARBARA HILL, PH.D.
`Pharmacologist
`Division of Dermatologic and Dental Drug Products
`
`ASSOCIATED REPORTERS OF WASHINGTON
`1523 North Carolina Avenue, N.E.
`Washington, D.C. 20002
`(202) 543-4809
`
`Page 4 of 271
`
`CFAD VI 1076 - 0004
`
`
`
`5
`
`APPEARANCES
`
`(Continued)
`
`FOOD AND DRUG ADMINISTRATION STAFF:
`
`(Continued)
`
`MURRAY LUMPKIN, M.D.
`Deputy Center Director for Review Management, COER
`
`LOUIS MORRIS, PH.D.
`Supervisory Psychologist
`Division of Drug Marketing, Advertising and Communications
`
`MARY PENDERGAST, J.D.
`Deputy Commissioner
`
`MICHAEL WEINTRAUB, M.D.
`Director, Office of Drug Evaluation V
`
`JONATHAN WILKIN, M.D.
`Director, Division of Dermatologic and Dental Drug Products
`
`JANET WOODCOCK, M.D.
`Director, Center for Drug Evaluation and Research
`
`CELGENE REPRESENTATIVES:
`
`WAYNE COLBURN, PH.D.
`DAVID R. CORNBLATH, M.D.
`ROBERT H. GELBER, M.D.
`STEVE THOMAS, PH.D.
`BRUCE WILLIAMS
`LEO YODER, M.D.
`JERRY ZELDIS, M.D., PH.D.
`
`ALSO PRESENT:
`
`CHRISTOPHER J. DOYLE
`JAMES W. HANSON, M.D.
`LEWIS B. HOLMES, M.D.
`LYNN M. KLEIN
`CYNTHIA PEARSON
`VICKI WALTON
`
`AS SOCIA TED REPORTERS OF WASHINGTON
`1523 North Carolina Avenue, N.E.
`Washington, D.C. 20002
`(202) 543-4809
`
`Page 5 of 271
`
`CFAD VI 1076 - 0005
`
`
`
`C 0 N T E N T S
`
`AGENDA ITEM
`
`CONFLICT OF INTEREST STATEMENT
`by Ms. Tracy Riley
`
`COMMISSIONER'S OFFICE STATEMENT -
`A New Chapter for Thalidomide and FDA
`by Ms. Mary Pendergast
`
`OFFICE DIRECTOR'S STATEMENT -
`An overview of the L.A. Data and an
`Overall Chronology of this NDA and
`the Interactions with Celgene Corp.
`by Dr. Michael Weintraub
`
`OPEN PUBLIC HEARING
`American College of Obstetricians and Gynecologists
`by Ms. Tracy Riley
`
`Leonard Wood Memorial American Leprosy Foundation
`by Ms. Tracy Riley
`
`American College of Medical Genetics, the American
`Academy of Pediatrics and the Academy Committee on
`Genetics - by Dr. James Hanson
`
`CELGENE CORPORATION PRESENTATION
`Chronology - Pharmaceutical Development
`By Dr. Steve Thomas
`
`Pharmacokinetics/Metabolism
`by Dr. Wayne Colburn
`
`LeprosyjENL - Clinical Use
`by Dr. Leo Yoder
`
`Safety and Efficacy
`by Dr. Jerry Zeldis
`
`Neuropathy
`by Dr. David Cornblath
`
`AS SOCIA TED REPORTERS OF WASHINGTON
`1523 North Carolina Avenue, N.E.
`Washington, D.C. 20002
`(202) 543-4809
`
`6
`
`PAGE
`
`9
`
`13
`
`17
`
`20
`
`20
`
`24
`
`28
`
`33
`
`45
`
`70
`
`105
`
`Page 6 of 271
`
`CFAD VI 1076 - 0006
`
`
`
`C 0 N T E N T S
`
`(Continued)
`
`AGENDA ITEM
`
`CELGENE CORPORATION PRESENTATION
`Fetal Exposure Prevention
`by Mr. Bruce Williams
`
`(Continued)
`
`7
`
`PAGE
`
`109
`
`OPEN PUBLIC HEARING
`
`American Leprosy Missions - by Mr. Christopher Doyle
`
`133
`
`American College of Medical Genetics
`by Dr. Lewis Holmes
`
`The Teratology Society - by Dr. Lewis Holmes
`
`National Organization for Rare Disorders
`by Ms. Lynn Klein
`
`National Women's Health Network
`by Ms. Cynthia Pearson
`
`American Behcet's Disease Association
`by Ms. Vicki Walton
`
`FDA PRESENTATION
`Opening Comments/Overview
`by Dr. Jonathan Wilkin
`
`Nonclinical Toxicology
`by Dr. Barbara Hill
`
`Clinical Pharmacology
`by Dr. Dennis Bashaw
`
`Overview on which to Base a Regulatory Action
`by Dr. Michael Weintraub
`
`Various Distribution Options
`by Dr. Murray Lumpkin
`
`Education Plan
`by Dr. Louis Morris
`
`AS SOCIA TED REPORTERS OF WASHINGTON
`1523 North Carolina Avenue, N.E.
`Washington, D.C. 20002
`(202) 543-4809
`
`137
`
`139
`
`141
`
`144
`
`151
`
`157
`
`164
`
`170
`
`187
`
`198
`
`207
`
`-
`
`-
`
`Page 7 of 271
`
`CFAD VI 1076 - 0007
`
`
`
`C 0 N T E N T S
`
`(Continued)
`
`AGENDA ITEM
`
`BIRTH DEFECTS DUE TO THALIDOMIDE EXPOSURE:
`CDC CONSIDERATIONS - by Dr. Cynthia Moore
`
`THALIDOMIDE NEUROTOXICITY
`by Dr. Colin Crawford
`
`8
`
`PAGE
`
`234
`
`251
`
`-
`
`ASSOCI A TED REPORTERS OF WASHINGTON
`1523 North Carolina Avenue, N.E.
`Washington, D.C. 20002
`(202) 543-4809
`
`Page 8 of 271
`
`CFAD VI 1076 - 0008
`
`
`
`~~
`
`--
`
`-
`
`P R 0 C E E D I N G S
`
`9
`
`(8:36a.m.)
`
`DR. McGUIRE: This is the 47th convening of the
`
`Dermatologic and Ophthalmic Drugs Advisory Committee
`
`meeting of the Food and Drug Administration.
`
`By the close of business tomorrow afternoon,
`
`this committee should have given the agency some
`
`recommendations on their evaluation of efficacy and safety
`
`of thalidomide. Thalidomide has played a very important
`
`role in the development of standards of the agency, and
`
`these should be very interesting discussions.
`
`I would like to turn the meeting over to Tracy
`
`Riley for the conflict of interest.
`
`MS. RILEY: Good morning. Welcome to the
`
`meeting.
`
`The following announcement addresses the issue
`
`of conflict of interest with regard to this meeting, and is
`
`made a part of the record to preclude even the appearance
`
`of such at this meeting.
`
`Based on the submitted agenda and information
`
`provided by the participants, the agency has determined
`
`that all reported interests in firms regulated by the
`
`Center for Drug Evaluation and Research present no
`
`potential for conflict of interest at this meeting.
`
`With respect to FDA's invited guest speaker,
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`ASSOCIATED REPORTERS OF WASIIINGTON
`(202) 543-4809
`
`Page 9 of 271
`
`CFAD VI 1076 - 0009
`
`
`
`---
`
`10
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`Mr. Randolph Warren, he has reported interests which we
`
`believe should be made public to allow the participants to
`
`objectively evaluate his comments. Mr. Warren would like
`
`to disclose that he has, on two occasions, discussed
`
`Synovir, thalidomide, with the Celgene Corporation.
`
`In the event that the discussions involve any
`
`other products or firms not already on the agenda for which
`
`an FDA participant has a financial interest, the
`
`participants are aware of the need to exclude themselves
`
`from such involvement and their exclusion will be noted for
`
`the record.
`
`With respect to all other participants, we ask,
`
`~ 13
`
`in the interest fairness, that they address any current or
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`previous financial involvement with any firm whose products
`
`they may wish to comment upon.
`
`Also there are four special government
`
`employees who are granted temporary voting status today to
`
`participate in this meeting: Dr. Wilma Bergfeld, Dr. Ken
`
`Hashimoto, Dr. Fred Miller, and Dr. Eva Simmons-O'Brien.
`
`And for the people at the table, there are
`
`additional review materials in your packet that you had not
`
`received before.
`
`Thank you.
`
`DR. McGUIRE: There will be introductory
`
`remarks from the agency, but before we hear those, I would
`
`ASSOCIATED REPORTERS OF W ASIIINGTON
`(202) 543-4809
`
`-
`
`Page 10 of 271
`
`CFAD VI 1076 - 0010
`
`
`
`-.
`
`-
`
`..... ~
`
`11
`
`like to start with the left ~nd of the table and have
`
`people sitting at the table introduce yourself, please.
`
`MR. WARREN:
`
`I am Randy Warren from the
`
`Thalidomide Victims Association of Canada.
`
`DR. SHANNON: My name is E.J. Shannon, from the
`
`Gillis Long Hansen's Disease Center in Carville, Louisiana.
`
`DR. CRAWFORD:
`
`I am Colin Crawford, from the
`
`London Imperial College, School of Medicine.
`
`DR. MOORE: Cynthia Moore for the Centers for
`
`Disease Control and Prevention.
`
`DR. MATHEWS: Chris Mathews, University of
`
`California, San Diego, and member of the Antiviral Advisory
`
`Committee.
`
`DR. DUVIC:
`
`I am Madeleine Duvic, from Houston,
`
`Texas, M.D. Anderson and UT.
`
`I am a dermatologist.
`
`DR. MINDEL:
`
`Joel Mindel, Departments of
`
`Ophthalmology and Pharmacology at Mount Sinai Medical
`
`Center, New York.
`
`DR. ORKIN: Milton Orkin, from the University
`
`of Minnesota, Minneapolis, Minnesota.
`
`DR. BERGFELD:
`
`I am Wilma Bergfeld, a
`
`dermatologist from the Cleveland Clinic.
`
`DR. McGUIRE:
`
`I am Joe McGuire, from Stanford
`
`University, dermatology and pediatrics.
`
`MS. RILEY:
`
`I am Tracy Riley, the Executive
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`ASSOCIATED REPORTERS OF WASHINGTON
`(202) 543-4809
`
`Page 11 of 271
`
`CFAD VI 1076 - 0011
`
`
`
`.-....
`
`-
`
`-
`
`12
`
`Secretary to the committee.
`
`DR. SIMMONS-O'BRIEN:
`
`I am Eva Simmons-O'Brien,
`
`from the Departments of Dermatology and Internal Medicine
`
`at Johns Hopkins in Baltimore, Maryland.
`
`DR. KILPATRICK:
`
`I am Jim Kilpatrick, School of
`
`Medicine, Medical College of Virginia, Virginia
`
`Commonwealth University, biostatistician.
`
`MS. COHEN:
`
`I am Susan Cohen, and I am the
`
`consumer member.
`
`DR. HASHIMOTO:
`
`I am Ken Hashimoto.
`
`I am a
`
`dermatologist, Wayne State University in Detroit.
`
`DR. MILLER: Fred Miller, dermatologist,
`
`Geisinger Medical Center, Danville, Pennsylvania.
`
`DR. BIRNKRANT:
`
`I'm Debra Birnkrant, acting
`
`Division Director, Division of Antiviral Drug Products, and
`
`I chair the Thalidomide Working Group at the FDA.
`
`DR. WILKIN:
`
`Jonathan Wilkin, FDA, Dermatologic
`
`and Dental Drug Products.
`
`DR. WEINTRAUB: Mike Weintraub, Office of Drug
`Evaluation v.
`
`DR. WOODCOCK:
`
`I'm Janet Woodcock, and I'm the
`
`head of the Center for Drug Evaluation and Research at the
`
`FDA.
`
`MS. PENDERGAST: Mary Pendergast, Deputy
`
`Commissioner, Food and Drug Administration.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`ASSOCIATED REPORTERS OF WASIIINGTON
`(202) 543-4809
`
`Page 12 of 271
`
`CFAD VI 1076 - 0012
`
`
`
`-
`
`~-
`
`~-
`
`DR. McGUIRE: Thank you very much.
`
`The first remarks will be presented by Mary
`
`13
`
`Pendergast.
`
`MS. PENDERGAST: Good morning. And thank you
`
`for coming to our Dermatologic and Ophthalmic Drugs
`
`Advisory Committee meeting.
`
`I would like to especially thank the Chairman
`
`and the other members of our advisory committee, who give
`
`so generously of their time and their expertise to the FDA.
`
`We are here so that our advisory committee can
`
`review Celgene's new drug application for the use of
`
`thalidomide for the treatment of erythema nodosum leprosum,
`
`abbreviated as ENL, a complication which occurs in a subset
`
`of patients with Hansen's disease, also known as leprosy.
`
`Last November we brought to this advisory
`
`committee our concept that thalidomide, despite its history
`
`and known risks, could be an approvable drug. We believed,
`
`and still believe, that thalidomide may have the capacity
`
`to treat as well as to damage. We also explained why we
`
`felt we needed to change the medical landscape when it came
`
`to thalidomide.
`
`Because thalidomide was not approved, patients
`
`with Hansen's disease were getting substandard drugs that
`
`were not manufactured under good manufacturing practices.
`
`And although thalidomide held out promise for other
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`ASSOCIATED REPORTERS OF WASHINGTON
`(202) 543-4809
`
`Page 13 of 271
`
`CFAD VI 1076 - 0013
`
`
`
`-
`
`-
`
`~ ..
`
`14
`
`diseases, there were no well-planned schemes for studying
`
`the drug for other diseases.
`
`The Health Resources Service Administration was
`
`running out of money to pay for the distribution of the
`
`drug under investigational new drug exemptions.
`
`And we were concerned about the proliferation
`
`of groups that were distributing bootleg, illegal
`
`thalidomide to patients with AIDS and cancer, without
`
`careful controls that would have prevented birth defects.
`
`Consequently, we took several steps to change
`
`the landscape. One step was to encourage companies to
`
`pursue approval for diseases for which there might be the
`
`requisite data. Celgene took up that challenge and has
`
`pulled together an application for the use of thalidomide
`
`for ENL, an indication for which the drug has been used for
`
`over 30 years.
`
`We also stopped the illegal distribution of
`
`thalidomide through buyers' clubs. Several clubs agreed
`
`voluntarily to stop distributing thalidomide. And we
`
`stopped the remaining buyers' clubs' activities through
`
`legal proceedings.
`
`We have also collaborated with the National
`
`Institutes of Health and the Centers for Disease Control to
`
`design a two-day public scientific meeting, that will be
`
`held next week, to explore whether and how thalidomide
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`ASSOCIATED REPORTERS OF WASHINGTON
`(202) 543-4809
`
`Page 14 of 271
`
`CFAD VI 1076 - 0014
`
`
`
`~
`
`15
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`could be used for other clinical uses. We know that
`
`thalidomide is being studied as a treatment for many
`
`serious diseases, including ENL, chronic graft versus host
`
`disease, cancer, and HIV infection.
`
`This meeting will discuss the advances and
`
`research opportunities of thalidomide in the treatment of
`
`various disorders.
`
`But next week's meeting will have a broader
`
`focus as well. We need to remember that more than half of
`
`the population alive today was not yet born when the
`
`thalidomide tragedy took place. There are many in our
`
`society, patients and physicians alike, who do not know the
`
`thalidomide story. Thus, as an education to some and as a
`
`reminder to others, we will also discuss the past uses of
`
`thalidomide, the risks associated with thalidomide and
`
`reproduction, the legal, ethical, and other public policy
`
`concerns surrounding thalidomide's use, and the management
`
`of the adverse effects of thalidomide.
`
`This will be an important and useful meeting,
`
`and the results of that meeting, as well as your expert
`
`advice today, will be taken into account before FDA makes
`
`any decision on the approvability of thalidomide for ENL or
`
`any other disease.
`
`I know that there are some who wish that next
`
`week's meeting could have been held before this meeting.
`
`ASSOCIATED REPORTERS OF WASIIINGTON
`(202) 543-4809
`
`~
`
`?'"~_
`
`Page 15 of 271
`
`CFAD VI 1076 - 0015
`
`
`
`~
`
`16
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`But scheduling difficulties made that impossible.
`
`In my
`
`view, though, it shouldn't matter. For today, we are
`
`attempting to have an ordinary advisory committee meeting.
`
`What we would like today is for the advisory
`
`committee to assist us with their expertise on the
`
`particular new drug application that is before them, and
`
`help us answer the question of whether thalidomide is
`
`effective in the treatment of ENL, and whether the steps
`
`that have been proposed to control the distribution and use
`
`of the drug will permit thalidomide to be considered safe
`
`under that scheme.
`
`Although these are the normal, straightforward
`
`questions we ask of advisory committee members all the
`
`time, they will be harder answers to come by today because,
`
`as you have seen, this is not a fully conventional data
`
`set. Celgene did not invent thalidomide and then develop
`
`the drug through conventional studies. Rather, thalidomide
`
`has been used for ENL for over 30 years without the
`
`rigorous collection of data one would expect from real
`
`clinical trials.
`
`Therefore, it is critically important to us
`
`that you give a careful and thoughtful look at the data
`
`that does exist, and help us decide whether thalidomide
`
`should be approved as a treatment for ENL. This will be
`
`challenging, but very important efforts, and we look
`
`ASSOCIATED REPORTERS OF WASIIINGTON
`(202) 543-4809
`
`~~
`
`ยง"""~
`
`Page 16 of 271
`
`CFAD VI 1076 - 0016
`
`
`
`~
`
`17
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`forward to hearing your deliberations.
`
`So, I would like to thank you again for being a
`
`member of our advisory committee, for helping us out on
`
`this very tough question. Thank you again for your
`
`attention.
`
`DR. McGUIRE: Thank you, Ms. Pendergast.
`
`Dr. Weintraub.
`
`DR. WEINTRAUB: Thank you, Dr. McGuire.
`
`Several people have asked, since we've
`
`distributed signed reviews, stating the reviewers'
`
`conclusions on the approval of thalidomide, why are we
`
`having an advisory committee meeting? And the question of
`
`people who oppose it, they said, well, you have already
`
`made up your minds; it is a closed issue. Well, I assure
`
`you that it is not.
`
`Let me tell you a little bit about the
`
`procedure at FDA. We believe that in a science-based
`
`enterprise, which this is, everyone is entitled to their
`
`own interpretation of the data -- particularly people who
`
`have worked very closely with the information coming from
`
`clinical trials or coming from studies such as these data
`
`sets, as Mary just pointed out. They are not always
`
`conventional data sets.
`
`But we do not demand that everybody has to have
`
`an opinion that is totally in concert with other opinions
`
`ASSOCIATED REPORTERS OF WASHINGTON
`(202) 543-4809
`
`-~
`
`~~
`
`Page 17 of 271
`
`CFAD VI 1076 - 0017
`
`
`
`~~
`
`,........_
`
`-
`
`18
`
`and other points of view. We believe in the value of ideas
`
`and of insights.
`
`Now, there are many reasons why a particular
`
`reviewer can come to a different judgment. The primary
`
`reviews are often completed earlier in the final approval
`
`process. And the reviewer may not have a total picture of
`
`the final plans -- for example, in this case, such as
`
`restricting distribution -- and perhaps, in that sense,
`
`altering the risk/benefit relationship.
`
`Of course, with a controversial drug such as
`
`thalidomide, there are bound to be differences of opinion.
`
`The outlook of everybody may be different when the drug is
`
`so controversial. Several people, all acting in good
`
`faith, can look at the same numbers, the same dots on a
`
`graph, and come to different conclusions. This is
`
`especially true if the numbers and dots come not from
`
`clinical trials but from experiences that were never
`
`intended to be interpreted as if they came from
`
`double-blind, randomized, carefully controlled
`
`experiments -- for example, things like the information
`
`from the clinical care of patients -- even those who are
`
`carefully followed.
`
`In the FDA, we have a system of supervisory
`
`oversight. That is why we have given you primary and
`
`secondary reviews, the Division Director's opinion and the
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`ASSOCIATED REPORTERS OF WASHINGTON
`(202) 543-4809
`
`Page 18 of 271
`
`CFAD VI 1076 - 0018
`
`
`
`-
`
`........
`
`#"'"
`
`~....__
`
`19
`
`Office Director's view.
`
`In ;ome cases, we have the
`
`Director of the Office of Review Management over the Office
`
`Director, and the Center Director as well.
`
`Except for the primary reviewer, we can all
`
`write overriding memoranda.
`
`I know that my colleagues --
`
`the other four office directors -- and I take overruling
`
`our trusted colleagues and coworkers very seriously.
`
`It is
`
`not something we do lightly.
`
`Instead, the decision
`
`involves delicate balances and inner struggles.
`
`So, although you have primary and secondary
`
`reviews and a Division Director's memo in your packet of
`
`materials, I will assure you that our minds are not made up
`
`and we are not done yet. Our analysis has not been locked
`
`in one way or the other.
`
`We invited you here because we respect your
`
`judgment. Even if we do not take your advice, as
`
`occasionally occurs, we still learn from your discussions,
`
`from your unique points of view, your questioning of the
`
`presenters, and your deliberations over the questions.
`
`Now,
`
`I am sure that we will still learn from
`
`your deliberations over the next day and a half, and I am
`
`certain that we will receive the benefit of your advice.
`
`I
`
`appreciate it, and I know actually the entire FDA is really
`
`in your debt for doing that.
`
`Thank you.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`ASSOCIATED REPORTERS OF WASIIINGTON
`(202) 543-4809
`
`Page 19 of 271
`
`CFAD VI 1076 - 0019
`
`
`
`-.
`
`-
`
`DR. McGUIRE: Thank you, Dr. Weintraub.
`
`I conclude from what you have said that this is
`
`20
`
`not a stacked deck.
`
`DR. WEINTRAUB: That is correct.
`
`DR. McGUIRE: Let's go on to the public
`
`hearing. There are two statements to be read.
`
`MS. RILEY: The first statement is from the
`
`Office of the Executive Director of the American College of
`
`Obstetricians and Gynecologists.
`
`On behalf of the American College of
`
`Obstetricians and Gynecologists, ACOG, an organization
`
`representing 38,000 physicians dedicated to improving the
`
`health care of women, ACOG does not believe that
`
`thalidomide, nor any drug, should be kept from being
`
`introduced or withdrawn from the market solely because it
`
`may be teratogenic. We strongly support efforts to prevent
`
`exposure of women who are pregnant or contemplating
`
`pregnancy from known teratogenic agents.
`
`Sincerely, Ralph W. Hale, M.D., Fellow of the
`
`American College of Obstetricians and Gynecologists.
`
`The next statement is from the Leonard Wood
`
`Memorial American Leprosy Foundation.
`
`I, Dr. Gerald P. Walsh, Scientific Director of
`
`the American Leprosy Foundation, am submitting a written
`
`presentation on behalf of my organization in support of the
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`ASSOCIATED REPORTERS OF W ASIIINGTON
`(202) 543-4809
`
`Page 20 of 271
`
`CFAD VI 1076 - 0020
`
`
`
`-
`
`~
`
`~ ,. '
`
`21
`
`licensing of thalidomide.
`
`I regret that at the time of the
`
`meeting it was necessary for me to be at our research
`
`facility in the Philippines.
`
`Founded in 1928, the Foundation conducts,
`
`maintains and supports laboratory investigations, clinical
`
`studies and related research, with the ultimate goal of
`
`eradicating leprosy. We also disseminate information about
`
`the source, diagnosis, treatment, and prevention of the
`
`disease, just as we voluntarily aid, establish, maintain,
`
`and support clinics, hospitals, and laboratories for
`
`diagnosis and treatment of the disease. The Foundation is
`
`headquartered in the United States, and maintains a leprosy
`
`research center in Cebu, Philippines. The Center is
`
`staffed by 34 individuals, composed of professional as well
`
`as technical and support staff. It is in Cebu that our
`
`scientific research is carried out. The Foundation is
`
`foremost among many American agencies in this field, and we
`
`are proud of the many achievements and contributions we
`
`have made that we believe will eventually lead to the
`
`eradication of this tragic disease.
`
`Few diseases are as feared and misunderstood as
`
`leprosy. Since pre-Biblical times, the leprosy patient has
`
`been surrounded by myth, superstition, fear, apathy, and
`
`rejection. Some progress has been made toward changing
`
`these attitudes, but unfortunately they are still prevalent
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`ASSOCIATED REPORTERS OF WASIIINGTON
`(202) 543-4809
`
`Page 21 of 271
`
`CFAD VI 1076 - 0021
`
`
`
`~
`
`-
`
`~--
`
`22
`
`in many parts of the world, including the United States.
`
`Contrary to popular thought, leprosy remains a
`
`major health problem in many developing countries, with
`
`more than 600,000 new cases detected annually. Today it is
`
`most prevalent in tropical and subtropical climates, but
`
`was rampant in temperate climates until the late 19th
`
`century. Of concern to this committee are the
`
`approximately 6,000 known cases of leprosy in the United
`
`States. The actual number of cases is undoubtedly higher,
`
`and climbing, in light of sustained immigration from Third
`
`World countries to the United States.
`
`Leprosy is currently treated with a combination
`
`of drugs. Although multi-drug therapy is the treatment of
`
`choice, serious problems still remain. New drugs are
`
`needed and research must continue.
`
`Up to 30 percent of all people afflicted with
`
`leprosy suffer from erythema nodosum leprosum, ENL, an
`
`acute reactional phase from leprosy that is very painful
`
`and debilitating for patients. It usually occurs after
`
`treatment is started and is characterized by the appearance
`
`of tender nodules, accompanied by fever and joint pain.
`
`In
`
`severe cases, the patients are bedridden for weeks. And
`
`some of these develop chronic ENL, which incapacitates a
`
`patient permanently. ENL is thought to be immunologically
`
`mediated, but the specific factors that precipitate
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`ASSOCIATED REPORTERS OF WASIIINGTON
`(202) 543-4809
`
`Page 22 of 271
`
`CFAD VI 1076 - 0022
`
`
`
`""'
`
`..
`
`-
`
`23
`
`episodes of ENL are not clearly understood. Recent studies
`
`have suggested that cytokines may play a key role in ENL.
`
`We at the American Leprosy Foundation are proud
`
`to have pursued research that addresses the key questions
`
`still surrounding the etiology and treatment on leprosy and
`
`ENL. We are very concerned that in our clinics today we
`
`can offer patients only a limited number of treatment
`
`options appropriate to their medical needs. This, of
`
`course, includes thalidomide, which the World Health
`
`Organization has determined is standard of care for the
`
`treatment of ENL.
`
`We recognize that thalidomide is restricted in
`
`that it cannot be used to treat pregnant women or, for that
`
`matter, women of childbearing age. But for the appropriate
`
`groups, it has the potential for enormous good in leprosy
`
`patients who develop ENL.
`
`In the words of the
`
`International Federation of Anti-Leprosy Associations, it
`
`is very effective for controlling ENL.
`
`Our studies in Cebu, Philippines, that are
`
`partially supported by Celgene Corporation, have shown the
`
`remarkable effect of thalidomide and represent an important
`
`treatment option for patients living with ENL. We at the
`
`American Leprosy Foundation urge you to recommend approval
`
`of this drug.
`
`Thank you.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`~
`
`ASSOCIATED REPORTERS OF WASHINGTON
`(202) 543-4809
`
`Page 23 of 271
`
`CFAD VI 1076 - 0023
`
`
`
`----
`
`~
`
`Gerald P. Walsh, Ph.D., Scientific Director.
`
`DR. McGUIRE: Thank you, Ms. Riley.
`
`We will have an oral presentation now from
`
`24
`
`Dr. James Hanson. Dr. James Hanson is representing the
`
`American College of Medical Genetics, the American Academy
`
`of Pediatrics and the Academy Committee on Genetics.
`
`DR. HANSON: Mr. Chairman, members of the
`
`committee, I am James Hanson, Professor of Pediatrics at
`
`the University of Iowa.
`
`I am here representing the
`
`American Academy of Pediatrics, as you have heard.
`
`It is not without reason that thalidomide has
`
`been termed the most notorious human teratogen. The drug
`
`was introduced in 1956 in West Germany, as an effective
`
`sedative and hypnotic.
`
`It was also used to treat nausea
`
`and vomiting in pregnancy. By the end of 1961,
`
`thalidomide, sold under S1 different brand names, was
`
`identified as a human teratogen and removed from the
`
`market. More than 10,000 infants worldwide were born with
`
`malformations attributed to the use of thalidomide in
`
`pregnancy.
`
`In 7 of the 17 cases reported in the United
`
`States, the thalidomide was purchased in another country.
`
`And I might add parenthetically that the
`
`avoidance of a similar tragedy in the United States was
`
`largely due to the efforts of Dr. Francis Kelsey, who is
`
`sitting over here on my left.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`~
`
`ASSOCIATED REPORTERS OF WASIIINGTON
`(202) 543-4809
`
`Page 24 of 271
`
`CFAD VI 1076 - 0024
`
`
`
`~
`
`25
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`(Applause.)
`
`DR. HANSON: The mechanism for teratogenicity
`
`of thalidomide is still not known. However, the period of
`
`greatest sensitivity appears to be between days 21 and 33
`
`of gestation. It is of great concern that the effects of
`
`thalidomide on the fetus do not appear to be dose-related,
`
`and teratogenic effects appeared in over 80 percent of the
`
`fetuses exposed during the critical period.
`
`Thalidomide produces major malformations of the
`
`upper extremities, ranging from missing thumbs to missing
`
`radii to absent ulnas and humeri, including so-called
`
`phocomelia and the micromelia.
`
`It sometimes produces major
`
`~ 13
`
`malformations of the lower extremities as well.
`
`In
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`2